![]() ![]() SENSEI BIOTHERAPEUTICS REGISTRATIONFinzoomers got registered with IRDAI as Corporate Agent (Composite) vide registration no. Sunny Bajajįinzoomers Services Private Limited (“Finzoomers”) carries out the business of referrer, intermediary, and facilitation, for varied financial services, including solicitation of insurance policies as a Corporate Agent(Composite). INA100012190 and is in the services and/or products, related to all kind of financial/ financial technology services, by using technology or otherwise, including but not limited to wealth management, financial technologies, investment advisory services, financial advice, financial analytics, distribution services and financial information.įinzoom Investment Advisors Private Limited - Investment Advisory Unit (Separately Identifiable Unit) Earlier stage programs include SNS-401, a ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA).įinzoom Investment Advisors Private Limited - Investment Advisory Unit (Separately Identifiable Unit) : is the holding Company which is registered with Securities Exchange Board of India as an investment advisor under SEBI (Investment Advisors) Regulations, 2013 (“IA regulations”) vide registration no. ![]() ![]() SENSEI BIOTHERAPEUTICS TRIALThe company’s most advanced immunotherapy, SNS-301, a first-in-class ImmunoPhage™ targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell Carcinoma of the Head and Neck. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. Using the ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf cocktail approach for treating cancer patients. The company has developed a proprietary bacteriophage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune system. For more information, please visit and follow the company on Twitter and LinkedIn.Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Sensei Biotherapeutics ( NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Portfolio managers and analysts who would like to request a meeting with management should contact their representative at the respective hosting firms. ( NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that Company management will participate in the following investor conferences in September 2022: 23, 2022 (GLOBE NEWSWIRE) - Sensei Biotherapeutics, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |